Vireo GrowthVREOF +2.36%46 Receivables Turnover is 7.38 as of Mar. 2026. GuruFocus rates VREOF with a GF Score™ of 46/100 and a GF Value™ of $9.69 (Fairly Valued). The stock has 6 warning signs investors should review. Among 947 Drug Manufacturers companies, Vireo Growth ranks better than 97.57% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Vireo Growth's Revenue for the
three
months ended in Mar. 2026 was $106.2 Mil. Vireo Growth's average Accounts Receivable for the
three
months ended in Mar. 2026 was $14.4 Mil.
Hence, Vireo Growth's Receivables Turnover for the
three
months ended in Mar. 2026 was 7.38.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Vireo Growth Receivables Turnover Related Terms
Vireo Growth Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Vireo Growth's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
VREOF vs ZTS, UTHR: Receivables Turnover Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Vireo Growth's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vireo Growth Receivables Turnover vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vireo Growth's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Vireo Growth's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vireo Growth (VREOF) has a Receivables Turnover of 7.38 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Vireo Growth and its competitors. According to the industry distribution chart, Vireo Growth ranks #23 out of 947 companies in the Drug Manufacturers industry, placing it in the top 2.4%.
Is Vireo Growth's Receivables Turnover too high?
Vireo Growth's current Receivables Turnover is 7.38. The Drug Manufacturers industry median Receivables Turnover is 5.07. Vireo Growth's value of 7.38 is 45.6% above this industry median. Based on the distribution chart, Vireo Growth ranks #23 out of 947 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Vireo Growth has a GF Score™ of 46/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Vireo Growth's Receivables Turnover compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Vireo Growth ranks #23 out of 947 companies for Receivables Turnover. This places Vireo Growth in the top 2% of its industry — outperforming the majority of peers. The industry median Receivables Turnover is 5.07. Vireo Growth's value of 7.38 is 45.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Drug Manufacturers company?
The median Receivables Turnover among Drug Manufacturers companies is 5.07, based on 947 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vireo Growth's current Receivables Turnover of 7.38 is 45.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Vireo Growth and its competitors. For the Drug Manufacturers industry, the median Receivables Turnover is 5.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vireo Growth's current Receivables Turnover is 7.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vireo Growth stock overvalued right now?
Based on GuruFocus' analysis, Vireo Growth (VREOF) is currently considered Fairly Valued. The stock's GF Value™ is $9.69, compared to a current price of $9.98 — trading 3% above its estimated fair value. The current Receivables Turnover is 7.38 and 45.6% above the Drug Manufacturers industry median of 5.07. Vireo Growth's overall GF Score™ is 46/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Vireo Growth (VREOF), the current Receivables Turnover is 7.38 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vireo Growth (VREOF) Overvalued in 2026?
Based on GuruFocus' analysis, Vireo Growth stock appears to be overvalued.
The current stock price of $9.98 is trading 3% above its estimated GF Value™ of $9.69.
GuruFocus considers Vireo Growth to be Fairly Valued.
Key valuation signals for VREOF:
Receivables Turnover: 7.38
GF Value™: $9.69 vs. price of $9.98 (3% above fair value)
Industry Position: 45.6% above the Drug Manufacturers median (#23 of 947)
No single metric tells the full story. See the VREOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vireo Growth Incis a cannabis company whose mission is to provide safe access, quality products and value to its customers while supporting its local communities through active participation and restorative justice programs. The Company is evolving with the industry and is in the midst of a transformation to being significantly more customer-centric across its operations, which include cultivation, manufacturing, wholesale and retail business lines. The company operates in one single segment.
46GF Score
Get the complete analysis for VREOF
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VREOF has been successfully added to your 
